Develops oncolytic immunotherapy drug candidates for cancer treatment, including therapies aimed at skin cancers and other solid tumors.
10-K for FY2026, filed Jun 29, 2026We are a clinical-stage biotechnology company committed to applying our leading expertise in the field of oncolytic immunotherapy to…View ↗
We have been conducting a number of clinical trials of RP1, both as a monotherapy and in combination with anti-PD-1 therapy, with the goal…View ↗
We are also developing or are continuing to develop additional product candidates, RP2 and RP3, that have been further engineered to…View ↗
No revenue reported yet.
10-K for FY2026, filed Jun 29, 2026
10-Q for Q2 FY2027, filed Oct 28, 2026
−$57.1MView ↗
8-K, filed Aug 14, 2026
TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 daysView ↗
8-K, filed Aug 7, 2026
WOBURN, Mass., August 6, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering…View ↗
Loading...